AG˹ٷ

STOCK TITAN

[144] Hewlett Packard Enterprise Company SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Form 4 filing for UnitedHealth Group (UNH) dated 07/02/2025 discloses routine quarterly equity compensation to non-employee director Paul R. Garcia.

  • Transactions (07/01/2025): 173 deferred stock units (immediately vested, must be held until board service ends) and 96 shares of common stock, both awarded at $0 cost.
  • Post-transaction ownership: 2,750 common shares held directly; 2,146 shares in a revocable trust; 45 and 55 shares in two additional trusts, for a total indirect holding of 2,246 shares.
  • No derivative securities were acquired or disposed of; the filing cites the awards as regular quarterly director compensation, not incentive-based or market purchases.

The filing is administrative in nature, with no impact on company operations, capital structure, or insider sentiment beyond customary board compensation.

Modulo 4 presentato da UnitedHealth Group (UNH) in data 02/07/2025 rivela la consueta compensazione azionaria trimestrale per il direttore non esecutivo Paul R. Garcia.

  • Operazioni (01/07/2025): 173 unità azionarie differite (con immediata maturazione, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-operazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale indiretto di 2.246 azioni.
  • Non sono stati acquisiti o ceduti strumenti derivati; la comunicazione indica che le assegnazioni sono compensazioni trimestrali regolari per il direttore, non basate su incentivi o acquisti di mercato.

La comunicazione ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la normale compensazione del consiglio.

Presentación del Formulario 4 de UnitedHealth Group (UNH) fechada el 02/07/2025 revela la compensación trimestral habitual en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (con adjudicación inmediata, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad posterior a la transacción: 2,750 acciones ordinarias en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total indirecto de 2,246 acciones.
  • No se adquirieron ni vendieron valores derivados; el reporte indica que las asignaciones son compensación trimestral regular para directores, no basadas en incentivos ni compras de mercado.

La presentación es de naturaleza administrativa, con ningún impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual del consejo.

2025� 7� 2일자 UnitedHealth Group(UNH) Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 즉시 취득되며 이사� 임기 종료 시까지 보유해야 하는 173개의 이연 주식 단위와 96주의 보통주를 각각 무상으로 수여받았습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; � 개의 추가 신탁� 각각 45주와 55�, 총간� 보유 주식은 2,246주입니다.
  • 파생 증권� 취득이나 처분은 없었으며, 제출 서류� � 상여가 인센티브 기반이나 시장 매수가 아닌 정규 분기� 이사 보상임을 명시합니�.

� 제출은 행정� 성격이며, 회사 운영, 자본 구조 또는 내부� 심리� 관� 관례적인 이사� 보상� 넘어서는 영향� 없습니다.

Dépôt du formulaire 4 de UnitedHealth Group (UNH) daté du 02/07/2025 révèle une compensation trimestrielle habituelle en actions pour le directeur non exécutif Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, à conserver jusqu’� la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que les attributions correspondent à une rémunération trimestrielle régulière des administrateurs, non basées sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l’entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung von UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide mit 0 $ Kosten zugeteilt.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 indirekt gehaltene Aktien.
  • Es wurden keine Derivate erworben oder veräußert; die Meldung bezeichnet die Zuwendungen als reguläre vierteljährliche Vergütung für Direktoren, nicht als leistungsabhängige oder marktbasierte Käufe.

Die Meldung ist administrativer Natur und hat keinen Einfluss auf den Geschäftsbetrieb, die Kapitalstruktur oder die Insiderstimmung über die übliche Vorstandsvergütung hinaus.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine director equity grant; neutral for valuation.

The reported acquisitions are standard board compensation—non-cash and immaterial relative to UNH’s 930 million shares outstanding. The director’s aggregate direct stake (�0.0003%) remains negligible, offering no meaningful signal of insider conviction or strategy shift. No derivatives, sales, or large block moves were disclosed, and there is no indication of upcoming corporate events. Consequently, the filing should be viewed as housekeeping rather than a catalyst.

TL;DR: Confirms UNH’s standard board pay structure; no red flags.

The grant aligns with prevailing S&P 500 director pay practice of quarterly stock/DSU awards to foster alignment with shareholders. Mandatory deferral of DSUs until board departure supports long-term oversight. No unusual acceleration clauses or special awards appear, indicating consistent, transparent governance. The filing poses no governance concerns and is non-impactful to investors.

Modulo 4 presentato da UnitedHealth Group (UNH) in data 02/07/2025 rivela la consueta compensazione azionaria trimestrale per il direttore non esecutivo Paul R. Garcia.

  • Operazioni (01/07/2025): 173 unità azionarie differite (con immediata maturazione, da mantenere fino alla fine del mandato nel consiglio) e 96 azioni ordinarie, entrambe assegnate a costo zero.
  • Possesso post-operazione: 2.750 azioni ordinarie detenute direttamente; 2.146 azioni in un trust revocabile; 45 e 55 azioni in due trust aggiuntivi, per un totale indiretto di 2.246 azioni.
  • Non sono stati acquisiti o ceduti strumenti derivati; la comunicazione indica che le assegnazioni sono compensazioni trimestrali regolari per il direttore, non basate su incentivi o acquisti di mercato.

La comunicazione ha natura amministrativa, con nessun impatto sulle operazioni aziendali, sulla struttura del capitale o sul sentiment degli insider oltre la normale compensazione del consiglio.

Presentación del Formulario 4 de UnitedHealth Group (UNH) fechada el 02/07/2025 revela la compensación trimestral habitual en acciones para el director no ejecutivo Paul R. Garcia.

  • Transacciones (01/07/2025): 173 unidades de acciones diferidas (con adjudicación inmediata, deben mantenerse hasta que finalice el servicio en la junta) y 96 acciones ordinarias, ambas otorgadas a costo cero.
  • Propiedad posterior a la transacción: 2,750 acciones ordinarias en propiedad directa; 2,146 acciones en un fideicomiso revocable; 45 y 55 acciones en dos fideicomisos adicionales, sumando un total indirecto de 2,246 acciones.
  • No se adquirieron ni vendieron valores derivados; el reporte indica que las asignaciones son compensación trimestral regular para directores, no basadas en incentivos ni compras de mercado.

La presentación es de naturaleza administrativa, con ningún impacto en las operaciones de la empresa, estructura de capital o sentimiento interno más allá de la compensación habitual del consejo.

2025� 7� 2일자 UnitedHealth Group(UNH) Form 4 제출�� 비임� 이사 Paul R. Garcia� 대� 정기 분기� 주식 보상� 공개합니�.

  • 거래 내역 (2025� 7� 1�): 즉시 취득되며 이사� 임기 종료 시까지 보유해야 하는 173개의 이연 주식 단위와 96주의 보통주를 각각 무상으로 수여받았습니�.
  • 거래 � 보유 현황: 직접 보유� 보통� 2,750�; 취소 가능한 신탁� 2,146�; � 개의 추가 신탁� 각각 45주와 55�, 총간� 보유 주식은 2,246주입니다.
  • 파생 증권� 취득이나 처분은 없었으며, 제출 서류� � 상여가 인센티브 기반이나 시장 매수가 아닌 정규 분기� 이사 보상임을 명시합니�.

� 제출은 행정� 성격이며, 회사 운영, 자본 구조 또는 내부� 심리� 관� 관례적인 이사� 보상� 넘어서는 영향� 없습니다.

Dépôt du formulaire 4 de UnitedHealth Group (UNH) daté du 02/07/2025 révèle une compensation trimestrielle habituelle en actions pour le directeur non exécutif Paul R. Garcia.

  • Transactions (01/07/2025) : 173 unités d’actions différées (acquises immédiatement, à conserver jusqu’� la fin du mandat au conseil) et 96 actions ordinaires, toutes deux attribuées à coût nul.
  • Possession après transaction : 2 750 actions ordinaires détenues directement ; 2 146 actions dans une fiducie révocable ; 45 et 55 actions dans deux autres fiducies, totalisant 2 246 actions détenues indirectement.
  • Aucun titre dérivé n’a été acquis ou cédé ; le dépôt précise que les attributions correspondent à une rémunération trimestrielle régulière des administrateurs, non basées sur des incitations ou des achats sur le marché.

Le dépôt est de nature administrative, sans impact sur les opérations de l’entreprise, la structure du capital ou le sentiment des initiés au-delà de la rémunération habituelle du conseil.

Formular 4 Einreichung von UnitedHealth Group (UNH) vom 02.07.2025 offenbart die routinemäßige vierteljährliche Aktienvergütung für den nicht geschäftsführenden Direktor Paul R. Garcia.

  • Transaktionen (01.07.2025): 173 aufgeschobene Aktienanteile (sofort unverfallbar, müssen bis zum Ende der Vorstandstätigkeit gehalten werden) und 96 Stammaktien, beide mit 0 $ Kosten zugeteilt.
  • Besitz nach der Transaktion: 2.750 Stammaktien direkt gehalten; 2.146 Aktien in einem widerruflichen Trust; 45 und 55 Aktien in zwei weiteren Trusts, insgesamt 2.246 indirekt gehaltene Aktien.
  • Es wurden keine Derivate erworben oder veräußert; die Meldung bezeichnet die Zuwendungen als reguläre vierteljährliche Vergütung für Direktoren, nicht als leistungsabhängige oder marktbasierte Käufe.

Die Meldung ist administrativer Natur und hat keinen Einfluss auf den Geschäftsbetrieb, die Kapitalstruktur oder die Insiderstimmung über die übliche Vorstandsvergütung hinaus.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many UnitedHealth Group shares did Paul R. Garcia acquire on 07/01/2025?

He received 96 shares of common stock and 173 deferred stock units as part of quarterly board compensation.

What is Paul R. Garcia’s total direct ownership in UNH after the transaction?

Following the award, he directly holds 2,750 common shares of UnitedHealth Group.

Are the deferred stock units (DSUs) immediately vested?

Yes. The DSUs vest immediately but must be held until the director’s service on the board ends.

Did the filing disclose any insider sales or derivative transactions?

No. The Form 4 reports only acquisitions of stock and DSUs; no sales or derivative activity were reported.

Does this Form 4 filing affect UnitedHealth Group’s share count?

No. The awards are sourced from the company’s existing equity compensation plan and do not materially alter the total shares outstanding.
Hewlett Packard Enterprise Co

NYSE:HPE

HPE Rankings

HPE Latest News

HPE Latest SEC Filings

HPE Stock Data

24.26B
1.31B
0.44%
85.93%
2.28%
Communication Equipment
Computer & Office Equipment
United States
SPRING